ArticleMolecular pharmaceutics2024

Evaluation of a Novel MET-Targeting Camelid-Derived Antibody in Head and Neck Cancer.

Rachel L Minne et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.